Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: A randomized, double-blind study

Hypertension Research

Volumn 40, Issue 3, 2017, Pages 251-258

  Higaki, Jitsuo ^a   Komuro, Issei ^b   Shiki, Kosuke ^c   Lee, Ganghyuck ^c   Taniguchi, Atsushi ^c   Ikeda, Hiroshi ^c   Kuroki, Daisuke ^c   Nishimura, Seiichiro ^c   Ogihara, Toshio ^d  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^d MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

Author keywords

amlodipine; combination therapy; hydrochlorothiazide; telmisartan

Indexed keywords

AMLODIPINE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE; PLACEBO; URIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DRUG COMBINATION; TELMISARTAN AMLODIPINE COMBINATION;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG COMBINATION; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85014677638     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.124     Document Type: Article

References (11)

1. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S, Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253-390.
2. Teramoto T, Toshiro F. Japan guideline assessment panel-2 (J-GAP2). Prog Med (Tokyo) 2010; 30: 1437-1449.
3. Nakagawa M, Masuda A, Ura N, Tanaka S. Transition of achievement rate for lowering blood pressure target level and situation of prescription for antihypertensive drug. J Blood Press 2011; 18: 73-77.
4. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SOF, Curry RW, Beitelshees AL, Chapman A, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Johnson JA. Predictors for glucose change in hypertensive participants following short-Term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy 2014; 34: 1132-1140.
5. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32: 1252-1269.
6. Mohan JC, Jain R, Chamle V, Bhargava A. Short term safety and tolerability of a fixed dose combination of olmesartan, amlodipine and hydrochlorothiazide. J Clin Diagn Res 2015; 9: OC10-OC13.
7. Machnicki G, Ong SH, Chen W, Wei ZJ, Kahler KH. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, health care utilization and costs. Curr Med Res Opin 2015; 31: 2287-2296.
8. Rakugi H, Tsuchihashi T, Shimada K, Numaguchi H, Nishida C, Yamaguchi H, Shirakawa M, Azuma K, Fujita KP. Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. Hypertens Res 2015; 38: 329-335.
9. Chrysant SG, Chrysant GS, Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. J Hum Hypertens 2005; 18: 172-183.
10. Konoshita TM, Makino Y, Kimura T, Fuji M, Wakahara S, Arakawa K, Inoki I, Nakamura H, Miyamori I, Genomic Disease Outcome Consortium (G-DOC) Study Investigators. A new-generation N/L-Type calcium channel blocker leads to activation of the renin-Angiotensin system compared with conventional L type calcium channel blocker. J Hypertens 2010; 28: 2156-2160.
11. Neutel J, Smith DH. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-Analysis of a clinical database. J Clin Hypertens 2003; 5: 58-63.